💉
Healthcare & Biotech Regulatory Redlines & Legal Risk 2007 - 2017

迈兰的肾上腺素笔定价 (Mylan / EpiPen):一支成本不高、必须随身携带的急救笔,为什么能涨到十倍价格?

在没有替代品的急救场景里,定价权等同于病人家属的支付能力

迈兰的肾上腺素笔定价 (Mylan / EpiPen):巅峰期全球性仿制药企业,旗下拥有用于严重过敏急救的自动注射笔,在美国市场的占有率长期处于主导地位;终局是产品价格在数年内大幅上涨引发公众与国会关注,随后公司因将其错误分类以降低医保回扣而与司法部达成巨额和解。

Official site
See the patterns
公开报道整理 待核查 Figures as of 2017 3 sources(1 primary) What do these mean?

How to read this bar

This bar states plainly what we know and what we have checked, so you can judge it yourself.

· Review status: “pending” means no editor has checked it against the sources yet; “checked” means key facts match the sources.

· Figures as of: the year the numbers are current to; later changes are out of scope.

· Sources: listed one by one at the bottom of the page. “Primary” means official filings, annual reports or regulator documents.

· Corrections: every change and its basis is published — nothing is edited silently.

Editorial policy → Editorial policy: the full inclusion rules, verification process, AI disclosure and correction promise.

No English translation for this case yet — showing the stored original.
Peak valuation

全球性仿制药企业,旗下拥有用于严重过敏急救的自动注射笔,在美国市场的占有率长期处于主导地位

Final cost

产品价格在数年内大幅上涨引发公众与国会关注,随后公司因将其错误分类以降低医保回扣而与司法部达成巨额和解

Attribution votes

4,350 votes cast

Community output

1 plans · 1 insights

Sponsored
把你亲历的失败写进来

投稿会先进入待审,通过后才进入公开目录和站点地图。

Root Causes Consensus Poll

Vote for the primary fatal error that caused this enterprise to collapse.

战略

在无替代品的急救场景中持续提价

患者缺少选择权,定价脱离成本与支付能力

1,431 votes (33%)
外部合规

医保分类处理不当

将产品按较低回扣类别申报,被认定为不当获取利益

1,202 votes (28%)
外部合规

对公众与政策反应估计不足

价格上涨的舆论风险未被提前纳入决策

973 votes (22%)
组织管理

推广强度与患者负担失衡

在扩大处方量的同时未提供可负担方案

744 votes (17%)

Sources

3 sources · 1 primary

These are the references used to compile this case; the numbers match the [1][2] marks in the timeline. Primary sources come first, and archive links are kept where possible.

1 of these are overseas sites (Wikipedia, the Internet Archive, etc.) that may be unreachable from mainland China, so domestic sources (Baidu Baike, mainstream financial media, exchange filings) have been added wherever possible.

  1. [1]
    官方网站(Wikidata 登记) Primary 官方资料
    mylan.com Accessed 2026-10-04
  2. [2]
    维基百科:Mylan 其他 Overseas site
    Wikipedia Accessed 2026-10-04
  3. [3]
    全球仿制药巨头盘点(三) | Mylan:闪耀的美利坚之星 媒体报道
    搜狐号 Accessed 2026-10-05